Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Assignment Title:
Submitted by:
FADM_171_Moh
Group Assignment 1
Group J3
PG ID
Anmol Mundhra
Abhishek Singh
Lakshmy Govind
Parul Abrol
61710426
61710565
61710170
61710699
(Let us not waste paper, please continue writing your assignment from below)
ISB Honour Code
I will represent myself in a truthful manner.
I will not fabricate or plagiarise any information with regard to the curriculum.
I will not seek, receive or obtain an unfair advantage over other students.
I will not be a party to any violation of the ISB Honour Code.
I will personally uphold and abide, in theory and practice, the values, purpose and rules of the ISB Honour Code.
I will report all violations of the ISB Honour Code by members of the ISB community.
I will respect the rights and property of all in the ISB community.
I will abide by all the rules and regulations that are prescribed by ISB.
Q1
Q2
194,762
170,223
182,493
111,302
90,801
101,052
22,179
29,255
148,189
131,556
125,387
128,472
77,122
70,844
73,983
7,028 Considering only
8,789 continuing operations
49,440
25,235
15,315
15,315
15,143
22,647
3,587
15,365
Yes
Yes
Yes
Yes
Profit Margin = Net Income + Income Tax Expense X (1- Tax Rate)
11,897
2,367
1,138
3,505
2,647
19,666
6,643
6,071
16,219
Yes
Yes
No
No
Q3
Q4
Value of
Sales
18,182
% Share
61%
21%
18%
% Change
-4.23%
-9.37%
-4.24%
% Share
14%
% Change
8.74%
North America-2015
North America-2015
70,743
48%
61,362
47%
15.29%
Russia and Other CISRussia and Other CIS2015
2015
17,713
12%
19,819
15%
-10.63%
Europe-2015
17,800
12%
Europe-2015
16,287
12%
9.29%
Others-2015
21,827
15%
Others-2015
16,065
12%
35.87%
Total
147855
Total
131,715
% Foreign Sales
87%
North America consitutes the largest share in sales. Others being the fastest growing segment and Russia
and other CIS report a decrease in revenue
Novartis External Sales Revenue(in Million USD)
Value of
Value of
Sales
Sales
Segment
% Share
Segment
% Share
% Change
Switzerland-2015
774
2%
Switzerland-2014
658
1%
17.63%
USA-2015
18,079
37%
USA-2014
17,337
33%
4.28%
UK-2015
1,277
3%
UK-2014
1,379
3%
-7.40%
Germany-2015
3,262
7%
Germany-2014
3,742
7%
-12.83%
France-2015
2,269
5%
France-2014
2,638
5%
-13.99%
Japan-2015
3,163
6%
Japan-2014
3,781
7%
-16.34%
Others-2015
20,590
42%
Others-2014
22,645
43%
-9.07%
Total
49,414
Total
52,180
% Foreign Sales
98%
USA constitutes the largest share in sales. Switzerland has the highest growth in sales and Japan shows
maximum % decrease in sales
Q5
As seen in Q3, 83% of Dr. Reddy's revene is generated from global generic medicine. Sandoz is the generic division of Novartis.
Thus, Sandoz is the part of Novartis that is the most likely direct competitor of Dr. Reddy's
Q6
Sales Revenues
COGS
Gross Margin %
Novartis has the highest gross margin percentage, followed by Dr. Reddy and Sandoz
The relationship makes sense because the Sandoz unit of Novartis derives its revenue only
from generic drugs. Dr. Reddy generates the majority of its revenue
from generic drugs, but its portfolio also contains specialized drugs which allows it to have a
higher gross margin than Sandoz.
Novartis derives a high percentage of its revenue from patented drugs, which being highly profitable allow it to earn the highest margin amongst all 3.
7
Company/Segment
DR REDDY'S
NOVARTIS
NOVARTIS SANDOZ
Operating Income
26,286
8,977
1,005
Total Revenue
Operating margin
148,189
17.74%
49,414
18.17%
9,157
10.98%
As evident from the calculations above, IFRS operating margins of Novartis are the highest which in turn signifiies
that Novartis makes highest profit(before interest and taxes) on each dollar of sales.
Below values have already been given in the Novartis balance sheet:
Core operating margin (%) 27.9
IFRS operating margin(%) 18.17%
Novartis has a discrepancy between the IFRS operating margin and core operating margin because the Groups core
results including core operating income, core net income and core earnings per share exclude the amortization
of intangible assets, impairment charges, expenses relating to divestments, the integration of acquisitions and
restructuring charges that exceed a threshold of USD 25 million, as well as other income and expense items that
management deems exceptional and that are or are expected to accumulate within the year to be over a USD 25
million threshold.
9
SEGMENT
Pharmaceuticals
Alcon
Sandoz
CORE OPERATING
MARGIN
IFRS OPERATING
MARGIN
30.94
31.22
18.12
As is evident from the reconcillation report on page 169 of Novartis financial report, Alcon as the higest discrepancy between IFRS ad Core
operating performance due to the higher value of Amortization of intangible assets for Alson i.e. 2063 which directly reduced the operating
margin from 31% in Core to 8% in IFRS.
24.95
8.09
10.98